Browse
Explore conditions, clinical trials, and the organisations running them.
Up to: Autosomal recessive disease · Disorder of phospholipids, sphingolipids and fatty acids biosynthesis · Inborn disorder of glycosphingolipid and glycosylphosphatidylinositol anchor glycosylation
GM3 synthase deficiency
GM3 synthase deficiency is characterized by recurrent seizures (epilepsy) and problems with brain development. Within the first few weeks after birth, affected infants become irritable and develop feeding difficulties and vomiting that prevent them from growing and gaining weight at the usual rate. Seizures begin within the first year of life and worsen over time. Multiple types of seizures are possible, including generalized tonic-clonic seizures (also known as grand mal seizures), which cause muscle rigidity, convulsions, and loss of consciousness. Some affected children also experience prolonged episodes of seizure activity called nonconvulsive status epilepticus. The seizures associated with GM3 synthase deficiency tend to be resistant (refractory) to treatment with antiseizure medications.
This condition has no sub-types.